Site-of-Care Shift for Physician-Administered Drug Therapies: 2026 Update

Using new Medicare data, this paper updates a prior analysis evaluating the site of care for all Medicare Part B drug therapies and finds that previously observed trends are continuing. Specifically, 340B Drug Pricing Program hospital outpatient departments (HOPDs)—including both HOPDs at the hospital itself and off-campus locations—continue to represent a growing share of outpatient drug administrations. This analysis also examines how these trends are reflected in top drugs used to treat breast cancer, rheumatoid arthritis, and multiple myeloma.

Findings include:

• Using Medicare claims data, the analysis shows that 38 percent of total Part B outpatient drug administrations in 2024 occurred in the 340B HOPD settings (including at child sites).
  • This was nearly twice the share of sales at 340B HOPDs settings in 2012.
• For specific disease states, the 340B HOPD setting’s share of total Part B claims re-priced at the average sales price (ASP) increased to:
  • 49 percent for breast cancer treatments in 2024, compared to 23.2 percent in 2012.
  • 51 percent for multiple myeloma treatments in 2024, compared to 19.8 percent in 2012.
• For treatments related to rheumatoid arthritis, the share of re-priced claims at 340B hospitals has remained between 20 and 22 percent since 2017.

This study was funded by the Pharmaceutical Research and Manufacturers of America.